The authors also found changes in stool metabolomics profiles which were associated with decreased expression of MS risk allele HLA.DPB1 (p = 0.078) as well as HLA.DPA1 (p = 0.055); this was also seen at the immune level where LBS administration induced an anti-inflammatory peripheral immune response characterized by decreased frequency of intermediate monocytes in patients with MS (p = 0.094). This evidence concerns the gene HLA-DPA1 and myeloid sarcoma.